8-K: Syndax Pharmaceuticals Reports Q3 2024 Results, Secures $350 Million Royalty Funding

Syndax Pharmaceuticals announced its third quarter 2024 financial results, highlighted by a $350 million royalty funding agreement and progress in its clinical pipeline.

Summary

• Syndax Pharmaceuticals reported its financial results for the third quarter of 2024, ending September 30, 2024.
• The company secured a $350 million royalty funding agreement with Royalty Pharma based on U.S. net sales of Niktimvo.
• Syndax expects this funding, along with anticipated product revenue and interest income, to enable the company to reach profitability.
• The company's cash, cash equivalents, and short and long-term investments totaled $399.6 million as of September 30, 2024.
• Research and development expenses for the third quarter increased to $71.0 million, up from $39.1 million in the same period last year.
• Selling, general, and administrative expenses also increased to $31.1 million, compared to $17.3 million in the prior year.
• The net loss attributable to common stockholders for the quarter was $84.1 million, or $0.98 per share, compared to a net loss of $51.1 million, or $0.73 per share, in the same quarter of 2023.
• Syndax anticipates the FDA approval and U.S. launch of revumenib for R/R KMT2Ar acute leukemia, with a PDUFA action date of December 26, 2024.
• Topline data from the AUGMENT-101 trial for R/R mNPM1 AML is expected in the fourth quarter of 2024, with a potential sNDA filing in the first half of 2025.
• Niktimvo has been approved by the FDA for chronic GVHD and is expected to launch in the U.S. no later than early first quarter 2025.

Sentiment

Score: 8

Explanation: The document presents a positive outlook with significant milestones achieved, including FDA approval for Niktimvo and a substantial royalty funding agreement. The clinical trial data is promising, and the company is well-positioned for future growth. However, the increased losses and expenses temper the overall sentiment slightly.

Positives

• The $350 million royalty funding agreement provides significant financial runway for the company.
• Niktimvo's FDA approval and upcoming launch represent a major milestone for Syndax.
• The company has a strong pipeline with multiple ongoing trials for revumenib and axatilimab.
• Positive data from the BEAT AML and SAVE trials indicate the potential of revumenib in combination therapies.
• The company is well-positioned to launch revumenib and leverage its first-to-market position.
• Niktimvo has been added to the NCCN Clinical Practice Guidelines as a category 2A recommendation for the treatment of GVHD.

Negatives

• The company reported a net loss of $84.1 million for the third quarter of 2024, which is an increase from the $51.1 million loss in the same period last year.
• Research and development expenses increased significantly to $71.0 million in the third quarter of 2024.
• Selling, general, and administrative expenses also increased to $31.1 million in the third quarter of 2024.

Risks

• The company's financial performance is dependent on the successful launch and commercialization of Niktimvo and revumenib.
• Clinical trial results may not always be positive, and there is a risk of unexpected safety or efficacy data.
• Regulatory approvals are not guaranteed, and there may be delays in the approval process.
• The company faces competition from other pharmaceutical companies in the oncology space.
• There is a risk of unexpected litigation or other disputes.

Future Outlook

Syndax expects to be funded through profitability with the recent royalty financing, anticipated product revenue, and interest income. The company anticipates the FDA approval and U.S. launch of revumenib and is preparing for the launch of Niktimvo. They also plan to initiate a pivotal trial of revumenib in combination with venetoclax and azacitidine by year-end 2024.

Management Comments

• Michael A. Metzger, Chief Executive Officer, stated that this has been a historic period for Syndax as they transitioned to a commercial-stage company with the approval of Niktimvo.
• He also mentioned that the company is well positioned to maximize the potential of their pipeline.
• Metzger noted that the company has a very exciting quarter ahead with the anticipated FDA approval and U.S. launch of revumenib and the expected readout of topline pivotal data from patients with R/R mNPM1 AML.

Industry Context

This announcement comes as the biopharmaceutical industry continues to focus on developing innovative cancer therapies. Syndax's progress with revumenib and Niktimvo positions them as a key player in the oncology space, particularly in the treatment of leukemia and GVHD. The royalty funding agreement is a common strategy for biotech companies to secure capital while retaining control of their assets.

Comparison to Industry Standards

• Syndax's 96% composite complete remission rate in the BEAT AML trial is very high compared to standard chemotherapy regimens for AML.
• The 88% overall response rate in the SAVE trial is also impressive, indicating a strong efficacy signal for the revumenib combination.
• The median duration of CR/CRh extended to 13 months for revumenib in the AUGMENT-101 trial is competitive with other targeted therapies in leukemia.
• The approval of Niktimvo for chronic GVHD addresses an unmet need in a difficult-to-treat patient population, similar to other recent approvals in this space such as belumosudil (Rezurock) from Kadmon Pharmaceuticals.
• The $350 million royalty financing is a significant amount, comparable to other royalty deals in the biotech sector, such as the recent deals by Vertex Pharmaceuticals and Biohaven Pharmaceuticals.

Stakeholder Impact

• Shareholders will benefit from the increased financial stability and potential for future growth.
• Employees will have job security and opportunities for advancement.
• Patients will have access to new and innovative cancer therapies.
• Customers will have access to new treatment options.
• Suppliers will have increased business opportunities.
• Creditors will have increased confidence in the company's ability to repay debts.

Next Steps

• The company anticipates the FDA approval and U.S. launch of revumenib for R/R KMT2Ar acute leukemia.
• Syndax expects to report topline data from the AUGMENT-101 trial for R/R mNPM1 AML in the fourth quarter of 2024.
• The company plans to launch Niktimvo in the U.S. no later than early first quarter 2025.
• Syndax plans to initiate a pivotal trial of revumenib in combination with venetoclax and azacitidine by year-end 2024.
• The company will present new clinical data at the 66th ASH Annual Meeting.

Key Dates

Keywords

Syndax Pharmaceuticals, Niktimvo, Revumenib, Axatilimab, Leukemia, GVHD, Oncology, Clinical Trials, FDA Approval, Royalty Funding